Mutations in ASXL1, RUNX1, TP53 or EZH2 negatively impact on the prognosis of MDS patients and it remains unclear whether standard-of-care regimens are sufficient to induce long-lasting effects in this patient population. Here, TP53 is linked to myelodysplastic syndrome.